Single-cell Sequencing Analysis of Resectable/Borderline Resectable Pancreatic Cancer Patients

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Total Enrollment

40 participants

Study Classification

OBSERVATIONAL

Study Start Date

2024-03-01

Study Completion Date

2026-09-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Preoperative neoadjuvant chemotherapy is widely used in treating patients with borderline resectable pancreatic cancer (BRPC). However, there are limitations in this field. Treatment strategies and definitions for BRPC patients differ, and the efficacy and prognosis of neoadjuvant chemotherapy vary greatly.This study aims to utilize single-cell sequencing technology to investigate in-depth the composition and interactions of the tumor microenvironment in patients from the surgical-only group and the preoperative neoadjuvant chemotherapy group.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Neoantigen mRNA Vaccines in Patients With Resectable Pancreatic Cancer

NCT06326736

Pancreatic Cancer

RECRUITING EARLY_PHASE1

Pancreatic Cancer With Elevated Serum CA125 Were Compared With Those Who Did Not Receive Neoadjuvant Chemotherapy.

NCT04835064

Pancreatic Adenocarcinoma

UNKNOWN PHASE3

Neoadjuvant Modified FOLFIRINOX in Borderline Resectable Pancreatic Cancer

NCT02749136

Pancreatic Adenocarcinoma

COMPLETED PHASE2

An Exploration of Candidates for Neoadjuvant Treatment in Resectable Pancreatic Cancer

NCT06129812

Pancreatic Cancer Neoadjuvant

COMPLETED

Neoadjuvant Nab-Paclitaxel and S-1 in Borderline Resectable Pancreatic Cancer

NCT03850769

Borderline Resectable Pancreatic Cancer

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pancreatic Neoplasms

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Borderline Resectable Pancreatic Cancer

Cancer tissue specimens can be collected postoperatively following neoadjuvant chemotherapy.

Single-cell Sequencing Analysis

Intervention Type DIAGNOSTIC_TEST

Identification of rare cell populations, the characterization of cell types and subtypes, and the discovery of novel cell states.

Resectable Pancreatic Cancer

Cancer tissue specimens can be directly collected postoperatively

Single-cell Sequencing Analysis

Intervention Type DIAGNOSTIC_TEST

Identification of rare cell populations, the characterization of cell types and subtypes, and the discovery of novel cell states.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Single-cell Sequencing Analysis

Identification of rare cell populations, the characterization of cell types and subtypes, and the discovery of novel cell states.

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* 18 years ≤ age ≤ 75 years.
* Resectable/borderline resectable pancreatic cancer patients diagnosed based on pathological and preoperative imaging evaluation.
* No prior history of any form of anti-tumor treatment.
* At least one measurable lesion.
* Eastern Cooperative Oncology Group (ECOG): 0-1.
* Not participated in any other clinical studies before or during treatment.
* Willingness to participate voluntarily in this study, signing an informed consent form.

Exclusion Criteria

* History of any other malignant tumor, except for completely resected basal cell or squamous cell carcinoma of the skin or carcinoma in situ of the cervix, within the past 5 years.
* Vaccination with live vaccines within 4 weeks prior to enrollment or during the study period.
* Active autoimmune diseases or a history of autoimmune diseases within the past 4 weeks before enrollment.
* Allogeneic bone marrow or organ transplantation.
* Active gastric or duodenal ulcers, ulcerative colitis, or active bleeding from unresected tumors in the gastrointestinal tract, or other conditions determined by the investigator that may cause gastrointestinal bleeding or perforation.
* Evidence or history of significant bleeding tendency within 3 months prior to enrollment (bleeding \>30 mL within 3 months, hematemesis, melena, or hematochezia), hemoptysis (\>5 mL of fresh blood within 4 weeks), or occurrence of thromboembolic events within 12 months (including stroke events and/or transient ischemic attacks).

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No